This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The outcomes estimated in the review were: the probabilities of neurodevelopmental impairment and death at home; the probability that apnoea requiring stimulation would not resolve spontaneously; the life expectancy for non-impaired infants; and the life expectancy for infants with cerebral palsy.
The probability estimates of the infants' characteristics contributing to apnoea were also assessed.
Study designs and other criteria for inclusion in the review
A systematic review of the literature does not appear to have been conducted. The design of the primary studies used was not reported. Two unpublished databases were also used.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
The effectiveness evidence was derived from four primary studies and two databases.
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
The probability values were 0.09 (range: 0.04 -0.09) for neurodevelopmental impairment, 0.85 (range: 0.73 -0.90) for death at home, and 0.0048 (0.0329) for risk that apnoea requiring stimulation would not resolve spontaneously.
Life expectancy was 75.3 years for non-impaired infants and 66.9 years for infants with cerebral palsy.
With respect to the infants' characteristics contributing to apnoea, the following estimates were used: the gestational age at birth was 24 -26 weeks for 39% of the sample, 27 -29 weeks for 45% of the sample, and more than 29 weeks for 16% of the sample; birth weight was 994 (+/-301) g; weight at discharge was 2,358 (+/-412) g;
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Page: 2 / 6 the use of antenatal corticosteroids therapy was 78%; the use of postnatal dexamethasone was 44%; the use of mechanical ventilation during admission was 82%; the use of methylxanthine therapy during admission was 93%; and the proportion of those discharged home on methylxanthine was 2%.
Methods used to derive estimates of effectiveness
The authors made some assumptions that were used in the decision model.
Estimates of effectiveness and key assumptions
It was assumed that the probabilities of neurodevelopmental impairment or death were 0 for apnoea developing in the hospital. The utility of temporary states was 1 both at home and at the hospital (for hospital, a value of 0 was used in the sensitivity analysis).
Measure of benefits used in the economic analysis
The summary benefit measures used were expected survival and the quality-adjusted life-years (QALYs). These were both derived from the decision model. An annual discount rate of 3% was applied. The utility values were derived from published evidence based on the Health Utility Index in patients of children born prematurely and control infants. However, these utility values were not reported.
Direct costs
Discounting was relevant, and an annual rate of 3% was applied since the time horizon of the study was lifetime. The unit costs were reported for the majority of items, but the quantities of resources used were not provided. The health services included in the economic evaluation were length of stay in the neonatal intensive care unit (NICU), diagnostic tests and procedures, professional time, resuscitation, ambulance, and neurodevelopmental impairment. Costs such as parental travel costs and child care in the neonatal period were not included. The cost/resource boundary of the thirdparty payer was adopted in the analysis of the direct costs. The resource use data were derived from authors' assumptions and published evidence. The costs were estimated from Medicare reimbursement rates for hospital data, then converted into true costs using the cost-to-charge ratio of the hospital from which the economic data were derived. Other costs were estimated from published studies and other databases. All the costs were converted into 2000 values, using the medical care component of the Consumer Price Index when necessary.
Statistical analysis of costs
The costs were treated deterministically in the base-case.
Indirect Costs
The indirect costs (i.e. productivity losses) were included in the analysis since the perspective of society was adopted in the study. The unit costs were reported separately from the quantities of resources used. The resource use data were based on authors' assumptions, while the costs came from US Bureau of Labor Statistics. The price year was 2000. Discounting was applied, as in the analysis of the direct costs.
The analysis of effectiveness was based on data derived mainly from published studies. However, a systematic review of the literature does not appear to have been undertaken. In addition, few details on the design of the primary studies, and the methods used to extract and then combine the data, were provided. Other data were derived from authors' assumptions. Overall, it was difficult to assess the validity of the estimates used. The uncertainty around these estimates was investigated in the sensitivity analysis.
Validity of estimate of measure of benefit
Both of the summary benefit measures were appropriate for detecting the impact of the interventions on the patients' health. Both are valid measures that are also comparable with the benefits of other health care interventions. The source of the utility values was reported. A decision model was constructed to derive these measures, which were discounted as recommended in the USA. The estimated benefits were not reported.
Validity of estimate of costs
The broadest perspective was adopted in the cost analysis. However, some categories of costs, such as parental travel expenses and child care in the neonatal period, were not included because of the lack of accurate information. However, the contribution of these items to the total costs was considered small. In general, the unit costs were not reported separately from the quantities of resources used, which limits the possibility of replicating the study. A breakdown of the cost items was provided, as was the price year, which would facilitate reflation exercises in other settings. No statistical tests were conducted on the costs at baseline, although sensitivity analyses were performed on the cost estimates. Information on resource use was unclear and was mainly derived from authors' assumptions.
